The objective of the study is to assess re-rupture rates and patient outcomes from subjects with at least 5 year follow up, treated with the JewelACL device for ACL reconstruction. The impact of fixation type and autograft augmentation will also be assessed. All adverse events related to the JewelACL device will be recorded. This study is Sponsored by Xiros.

Inclusion Criteria:

• Age more than 18 years
• Patients previously implanted with the JewelACL for Anterior Cruciate Ligament (ACL) reconstruction (Primary JewelACL cases only, no revision cases)

Exclusion Criteria:

• Age less than 18 years
• Any implantations for non-indicated conditions, as stated in the Instructions For Use Instructions for use (IFU)
• Revision cases

Consecutive patients who have had the JewelACL device used to reconstruct the ACL, between the period of 01 October 2010 to 31 December 2014.

From time of surgery to the minimum follow up period (5 years post surgery)

AE: Any untoward medical occurrence, unintended disease or injury or any untoward clinical signs, in subjects, users or other persons, in the context of a clinical investigation, whether or not related to the investigational device.

SAE: Any AE that led to: death,serious deterioration in the health of the subject, permanent impairment to a body structure or a body function,chronic disease,foetal distress, foetal death or a congenital physical or mental impairment or birth defect

Reruptures can be sustained during sports trauma and cannot necessarily be attributed to device insufficiency.